Stay updated on VAX-24 Safety and Immunogenicity in Adults Clinical Trial
Sign up to get notified when there's something new on the VAX-24 Safety and Immunogenicity in Adults Clinical Trial page.

Latest updates to the VAX-24 Safety and Immunogenicity in Adults Clinical Trial page
- Check2 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference1%
- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check31 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check45 days agoChange DetectedThe page has undergone significant updates, including the addition of new details about the VAX-24 pneumococcal vaccine and its clinical study design, while removing extensive descriptions of the study's objectives and criteria.SummaryDifference26%
- Check52 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check96 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check110 days agoChange DetectedThe web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to VAX-24 Safety and Immunogenicity in Adults Clinical Trial
Enter your email address, and we'll notify you when there's something new on the VAX-24 Safety and Immunogenicity in Adults Clinical Trial page.